At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Prebiotic +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fiber Supplementation In Children With Peanut Allergy On Oral Immunotherapy: A Randomized Controlled Pilot Study
In Brief
A Phase 2 clinical trial evaluating Prebiotic and Placebo for Peanut Allergy. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
The purpose of this research is to gather information on the safety and efficacy of using a prebiotic as an adjunctive therapy to peanut oral immunotherapy. The prebiotic is not an FDA approved drug or medication rather a fiber found at local grocery stores.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Allergy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedDec 2021
Primary CompletionMar 2025
TodayJul 2026
First PostedDec 1, 2021
Enrollment StartNov 30, 2021
Primary CompletionMar 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 4.6 years ago
Interventions
Prebioticdrug
A prebiotic is a purified fiber of plant origin that has digestive health benefits by fostering the growth of beneficial microbes.
Placebodrug
A placebo is a substance that has no therapeutic effects used as a control while testing new drugs.